🔗 Share this article

As the US proceeds with unprecedented revisions to its vaccine recommendations, one figure has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations in the global health crisis and has focused upon potential deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Public health authorities were set to reveal sweeping changes to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with much of the world with no evidence for improved outcomes. The announcement has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more in line with the Danish model, a nation with comprehensive healthcare and a population approximately the population of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious track record in drug development, oversight or management, which has been customary for former directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an vast portfolio at the agency, Woodcock pointed out.

“Many people just focuses on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be managed,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a major leadership aspect to the role, which manages more than 5,000 employees. “It is a huge management job, if you do it right,” Woodcock concluded.

Response and Contentious Initiatives

Regarding inquiries about Dr. Høeg's qualifications and whether this selection represents greater collaboration among regulatory chiefs on vaccines, a representative responded that the “questions are based on inaccurate assumptions”.

“This background aligns with the responsibilities of her role,” the representative said, pointing to the period Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's new priority voucher program, a controversial one-day drug-approval program that apparently worried her former heads. “How are these drugs being selected for this expedited pathway? Who makes the decisions?” Howard said. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards laxer rules of most medications, aside from vaccines.”

Public Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, track record, critics observe. She published a study using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the current government included changing regulations for recently developed shots and ending “optional” immunizations, she said post-election on a podcast. At the agency, Høeg has allegedly proposed barring teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who commences with her conclusions and works backwards to fit the data in a extremely disingenuous, untruthful way,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|